Document:

EX-10.13

 Exhibit 10.13 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 Dated 10 June 2005 

(1) SCYNEXIS, Inc. 
 -
and - 
 (2) C-CHEM AG 
  

 
 Agreement for
the Assignment of Patents and Know How 
 concerning Cyclosporin Derivatives 

 
  

  
 1 

 THIS AGREEMENT is made the 10th day of June 2005 

BETWEEN:- 
  

	(1)	SCYNEXIS, Inc., a corporation incorporated under the laws of Delaware having its principal place of business at 3501C Tricenter Boulevard, Durham, North Carolina, 27713, United States of America
(“Scynexis”); and 

  

	(2)	C-CHEM AG, a company incorporated under the laws of Switzerland having its principal place of business at Bundesplatz 12, CH-6300 Zug, Switzerland (“C-CHEM”). 

BACKGROUND:- 
  

	(A)	C-CHEM has developed or acquired inventions and know-how concerning cyclosporine derivatives, and owns certain patents relating to such inventions. 

 

	(B)	C-CHEM and Scynexis entered into an Option Agreement dated 17 February 2004 under which C-CHEM granted Scynexis an option to obtain an assignment of the entire right, title and interest in such
inventions, know-how and patents (the “Option Agreement”). 

  

	(C)	Pursuant to the Option Agreement, C-CHEM is willing to assign and Scynexis wishes to receive such assignment of C-CHEM’s inventions, know-how, and patents concerning cyclosporin derivatives in accordance with
and subject to the provisions of this Agreement. 

 THE PARTIES AGREE AS FOLLOWS:- 

 

	1.	Definitions 

 In this Agreement the following words and expressions shall have the
following meanings:- 
  

					
	1.1.	 	 “Affiliate”	  	means any company or other legal entity which, now or hereafter, directly or indirectly, owns or controls, is owned or controlled by or is under common ownership or control with a party to this Agreement. In the case of legal
entities having stock and/or shares, ownership or control shall exist through the direct or indirect ownership and/or control of more than fifty percent of the voting stock or shares. In the case of any other legal entity, ownership and/or control
shall exist through the ability to directly or indirectly control the management and/or business of the legal entity;

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 2 

					
	1.2.	 	“Ancillary Rights”	  	any copyrights, design rights, database rights and/or similar rights that subsist in the Documentation;
			
	1.3.	 	“Assignment”	  	the patent assignment to be executed by C-CHEM and Scynexis on the Commencement Date;
			
	1.4.	 	“Commencement Date”	  	the date of this Agreement as written at the start of this Agreement;
			
	1.5.	 	“Compound”	  	means a Compound [*] or a Compound [*];
			
	1.6.	 	“Compound [*]”	  	any compound, whose manufacture, sale or use falls within the scope of a Valid Claim of [*]. Included are any and all compounds [*];
			
	1.7.	 	“Compound [*]”	  	any compound, whose manufacture, sale or use falls within the scope of a Valid Claim of [*]. Included are any and all compounds, [*];
			
	1.8.	 	“Documentation”	  	the documents and files (whether in paper, electronic or other form) (1) in the possession or control of C-CHEM containing the Know How and/or (2) contained in the prosecution files for the Patents and any original title
documents relating to the Patents including the original patent office filing receipts, original renewal certificates;
			
	1.9.	 	“Holding Party”	  	the party that under the provisions of Clauses 14.1 and 14.2, does not own the Confidential Material concerned;
			
	1.10.	 	“Information”	  	data, results, know-how, show-how, software, algorithms, inventions, designs, trade secrets, plans, forecasts, analyses, evaluations, research, technical information, concepts, techniques, processes, business information,
financial information, business plans, strategies, customer lists, marketing plans, or other information whether oral, in writing, in electronic form or in any other form;
			
	1.11.	 	“Inventions”	  	the inventions described in the Patents:
			
	1.12.	 	“Inventors”	  	[*];
			
	1.13.	 	“Know How”	  	the Information in the possession of and/or controlled by C-CHEM that was disclosed to Scynexis as part of Scynexis’ due diligence process in the year 2004, which Information is described in Schedule 2.
			
	1.14.	 	“Licensee”	  	any third party to whom Scynexis has granted a licence

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 3 

							
		 		    	under the Patents;
			
	1.15.	 	“Net Sales Value”	    	the gross amount invoiced by or on behalf of Scynexis and any sublicensee for Product sold to third parties other than Licensees, less the following deductions, determined in accordance with Scynexis’ standard
accounting methods:
				
		 		    	(i)	  	trade and quantity discounts;
				
		 		    	(ii)	  	 amounts repaid or credited by reasons of defects, rejection recalls, returns, shortages, rebates and allowances of goods or because of
retroactive price reductions;

				
		 		    	(iii)	  	chargebacks and other amounts paid on sale or dispensing of such Product, including sales commissions paid to distributors and/or selling agents;
				
		 		    	(iv)	  	amounts payable resulting from governmental (or agency thereof) mandated rebate programes;
				
		 		    	(v)	  	third-party cash rebates and chargebacks related to sales of the finished Product;
				
		 		    	(vi)	  	tariffs, duties, excise, sales, value-added and other taxes;
				
		 		    	(vii)	  	retroactive price reductions allowed or granted;
				
		 		    	(viii)	  	cash discounts for timely payment;
				
		 		    	(ix)	  	delayed ship order credits;
				
		 		    	(x)	  	discounts pursuant to indigent patient programs and patient discount programs, including, without limitation, “Together Rx” and coupon discounts;
				
		 		    	(xi)	  	freight, postage and insurance charges;
				
		 		    	(xii)	  	any other amounts included in the Product’s gross invoice that should be credited for reasons substantially equivalent to those listed above;
			
	 1.16.
	 	 “Owning Party”
	    	the party that owns the Confidential Material concerned as specified in Clauses 14.1 and 14.2;

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 4 

							
	 1.17.
	 	 “Patents”
	    	means:
				
		 		    	(a)	  	the patents and patent applications listed in Schedule 1 as LÜCH-1 and E11-1,
				
		 		    	(b)	  	any and all foreign counterparts, and any patents and patent applications anywhere in the world claiming, or entitled to claim, priority from any of the patents and patent applications listed in Schedule 1, and any patents issued or
issuing on any of such applications,
				
		 		    	(c)	  	any provisional and non-provisional applications anywhere in the world, including certificates of invention and applications for certificates of invention, claiming Inventions and any patents issued or issuing on any such
applications,
				
		 		    	(d)	  	any continuations, divisions, continuations-in-part, re-examinations, renewals, supplementary protection certificates, patents of addition, utility models of any of the foregoing and any patents issued or issuing thereon,
and
				
		 		    	(e)	  	any reissues and extensions of any of the foregoing;
			
	 1.18.
	 	 “Personnel”
	    	means in respect of a party, its officers, employees, consultants, agents, representatives, contractors and advisors;
			
	 1.19.
	 	 “Products”
	    	means any product containing a Compound;
			
	 1.20.
	 	 “Quarter”
	    	the quarterly periods ending 31 March, 30 June, 30 September and 31 December; and
			
	 1.21.
	 	 “Valid Claim”
	    	any claim contained in a subsisting granted Patent that has not been held invalid or unenforceable by a final decision of a court or other government agency of competent jurisdiction that is unappealable or has not been
appealed within the time allowed for appeal and which has not been admitted to be invalid or unenforceable through reissue disclaimer or otherwise.

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 5 

	2.	Patents 

  

	2.1.	On the Commencement Date, C-CHEM shall assign to Scynexis all right, title and interest in the Patents by executing an assignment of the Patents in the form set out in Schedule 3. 

 

	2.2.	C-CHEM shall at the request of Scynexis promptly do all acts and execute all documents as may be necessary or desirable to vest in Scynexis all right, title and interest in the Patents and to record Scynexis as the
proprietor of the Patents in any country. 

  

	2.3	C-CHEM shall at the request of Scynexis agree in good faith a fair, reasonable and appropriate apportionment of the consideration payable under this Agreement in respect of the assignment of each Patent.

  

	2.4.	C-CHEM will perform the assignment of the Patents, i.e. communicate with the corresponding patent attorneys and patent offices, collect the necessary documents and signatures and bear all arising internal costs, and
Scynexis will bear all external costs, i.e. fees from external patent attorneys and patent offices. 

  

	2.5.	C-CHEM shall not and shall procure that its Affiliates and Personnel shall not, challenge, oppose or otherwise dispute (or directly or indirectly assist any third party to challenge, oppose or otherwise dispute) the
ownership, validity and/or scope of any of the Patents. 

  

	3.	Know How and Documentation 

  

	3.1.	With effect from the Commencement Date, C-CHEM assigns to Scynexis all right, title and interest in the Know How. Scynexis and its Personnel shall have the full unfettered and exclusive worldwide right to disclose and
use the Know How for any purpose whatsoever. 

  

	3.2.	Within 15 days of the Commencement Date, C-CHEM shall transfer and deliver to Scynexis in good order the Documentation. 

  

	3.3.	With effect from the Commencement Date, all right, title and interest in the Documentation and the Ancillary Rights shall vest in Scynexis. C-CHEM shall at the request of Scynexis promptly do all acts and execute all
documents as may be necessary or desirable to vest in Scynexis all right, title and interest in the Documentation and the Ancillary Rights. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 6 

	4.	Non-Exclusive Licence Grant 

 In the event the development, making, having made, use, or
sale of Products by Scynexis, its Affiliates or Licensees would infringe any other intellectual property which C-CHEM owns at the Commencement Date or has the rights to license (other than the Patents, Know How, Documentation and Ancillary Rights),
C-CHEM hereby grants to Scynexis, a non-exclusive, world-wide, royalty-free, sub-licensable license under such other intellectual property solely for Scynexis, and its Affiliates and Licensees to develop, make, have made, use and sell Products. 

 

	5.	Technology Transfer 

  

	5.1.	C-CHEM shall respond promptly to reasonable enquiries made by Scynexis in respect of the Patents and the Know How provided that C-CHEM shall not be required to carry out any further research or experiment, in order to
respond to any such enquiry. 

  

	5.2.	C-CHEM shall procure that Personnel of C-CHEM and/or its Affiliates who have knowledge of the Patents and the Know How are available for telephone discussions, and meetings with Scynexis at the C-CHEM facilities, and
facilitate to its best efforts meetings with the Inventors and with C-CHEM’s patent counsel, as and when reasonably required by Scynexis. 

  

	5.3.	C-CHEM shall as and when reasonably requested by Scynexis, provide copies of any documents or files in the possession or control of C-CHEM or its Affiliates that may reasonably assist Scynexis with its understanding of
the Patents and the Know How provided that C-CHEM shall not be required to provide copies of any documents or files in breach of a duty of confidence owed to a third party. 

 

	6.	Payments 

  

	6.1.	In consideration of the assignment and transfer of the Patents, the Know How, the Documentation and the Ancillary Rights and subject to the provisions of this Clause 6, Scynexis shall pay to C-CHEM the following
amounts, such amounts to be non refundable and non creditable against any subsequent payments due under this Agreement; 

  

	 	6.1.1.	the sum of [*] United States dollars (US [*]) within [*] after the Commencement Date; and 

  

	 	6.1.2.	the following milestone payments which shall be paid within [*] after the date that the milestone is obtained: 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 7 

					
	 	  	 Milestone
	  	 Milestone Payment

			
	 1.
	  	[*]	  	 [*] United States dollars
  

(US $[*]).

			
	 2.
	  	[*]	  	 [*] United States dollars
  

(US $[*]).

			
	 3.
	  	[*]	  	 [*] United States dollars
  

(US $[*]).

 and 
  

	 	6.1.3.	a royalty of [*] of the Net Sales Value of all Products as defined in 1.19 sold by Scynexis or any Affiliate of Scynexis that fall within the scope of one or more Valid Claims in the country in which the sale took
place; and 

  

	 	6.1.4.	a royalty of [*] of the Net Sales Value of all Products as defined in 1.19 sold by a Licensee that fall within the scope of one or more Valid Claims in the country in which the sale took place. 

 

	6.2.	In no circumstances shall Scynexis be required to pay C-CHEM a royalty in respect of a Product under both Clauses 6.1.3 and 6.1.4. 

  

	6.3.	If a compulsory license is granted to a third party with respect to a Product in any country with a royalty rate lower than the royalty rate provided in Clause 6.1.4 then: 

 

	 	6.3.1	the royalty rate to be paid to C-CHEM in respect of sales [*] in that country shall be [*]; and 

  

	 	6.3.2	the royalty rate in respect of sales of Products [*] in such country shall be [*]. 

  

	6.4.	If laws, rules or regulations require withholding of taxes imposed upon the payments set forth in this Agreement, [*] such withholding payments from the payments due to C-CHEM set forth in this Clause 6. C-CHEM shall
execute any documentation reasonably necessary to allow Scynexis to reduce or eliminate any such withholding taxes. 

  

	6.5.	No royalties shall be payable under the Agreement on the sale or transfer among Scynexis, its Affiliates or Licensees, but in such cases the royalty shall be due and calculated upon Scynexis’ or its
Affiliate’s or Licensee’s Net Sales Value to the first independent third party. 

  

	6.6.	No royalties shall be payable under this Agreement on the disposition of Products by Scynexis, its Affiliates and Licensees as samples (promotional or otherwise) or as donations (for example, to non-profit institutions
or government agencies for a non-commercial purpose). 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 8 

	6.7.	The royalties described in Clauses 6.1.3. and 6.1.4. shall be reduced if and to the extent Scynexis can demonstrate to C-CHEM that Scynexis or its Affiliates or Licensees or distributors have not been able to actually
collect royalties despite having undertaken commercially reasonable enforcement activities. 

  

	6.8.	In the event the Product is sold in a finished dosage form containing the Product in combination with one or more other active ingredients (a “Combination Product”), the Net Sales Value of the Product, for the
purposes of determining royalty payments, shall be determined by multiplying the Net Sales Value (as defined above) of the Combination Product by the fraction, A/(A+B) where A is [*] in the particular country of the Product when sold separately in
finished form and B is the [*] in that country of the other product(s) sold separately in finished form. In the event that such average sale price cannot be determined for both the Product and the other product(s) in combination, the Net Sales Value
for purposes of determining royalty payments shall be agreed by the parties based on the relative value contributed by each component. 

  

	7.	Payment Terms 

  

	7.1.	Starting from when the first Product is put on the market for commercial sale in a country covered by a Patent then in force, within [*] of the end of each subsequent Quarter, Scynexis shall; 

 

	 	7.1.1.	provide C-CHEM with a royalty statement for that Quarter setting out the royalties payable in respect of sales of Products made during that Quarter under Clause 6; and 

 

	 	7.1.2.	pay the sums due to C-CHEM as set forth in such royalty statement. 

  

	7.2.	All sums payable under this Agreement shall be paid in US Dollars by direct transfer to C-CHEM’s bank account, details of which C-CHEM shall notify to Scynexis as and when necessary. 

 

	7.3.	If Products are sold or supplied by Scynexis, its Affiliates and/or Licensees in a currency other than US Dollars, the royalties payable in respect of such sales under this Agreement shall be first determined in the
currency of invoice and then converted into US Dollars at the average daily open market currency rate as quoted in the Wall Street Journal for the Quarter in which such sales took place. 

 

	7.4.	If Scynexis fails to pay any sum due under this Agreement in full by the due date for payment then C-CHEM may, without prejudice to any other right or remedy available to C-CHEM, charge interest on any outstanding
amount on a daily basis at a rate equivalent to the London Inter-Bank Offer Rate (6 months) [*]. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 9 

	8.	Records and Audits 

  

	8.1.	Scynexis shall keep at its normal place of business records and books of account showing the quantity, description and value of all Products sold by Scynexis and its Affiliates in each country for a period of [*] after
the sale took place. 

  

	8.2.	Scynexis shall make its records and books of account available for inspection during normal business hours by an independent professional accountant appointed by C-CHEM for the purpose of verifying the accuracy of any
royalty-statement provided by Scynexis to C-CHEM pursuant to Clause 7.1 in the previous [*] provided that the accountant enters into a binding confidentiality agreement with Scynexis in the form reasonably requested by Scynexis. 

 

	8.3.	C-CHEM shall be entitled to have inspections carried out pursuant to Clause 8.2 [*] on giving Scynexis [*] written notice prior to each inspection. 

 

	8.4.	C-CHEM shall bear the cost of carrying out the inspections referred to in Clause 8.3 unless there is a shortfall of more than [*] in any royalty statement provided by Scynexis, in which case Scynexis shall promptly pay
to C-CHEM the accountants’ reasonable fees for making the relevant inspection. 

  

	9.	Representations and Warranties 

  

	9.1.	Each party represents and warrants to the other that it has the legal right and power to enter into this Agreement and to fully perform its obligations hereunder. 

 

	9.2.	C-CHEM represents and warrants to Scynexis that as of the Commencement Date: 

  

	 	9.2.1.	the Patents set out in Schedule 1 exist and, to the best of C-CHEM’s knowledge, are not invalid or unenforceable in whole or in part; 

 

	 	9.2.2.	to the best of C-CHEM’s knowledge, the Inventors have not assigned the Inventions or any rights relating thereto, to any employer, former employer or other entity, and have not entered into any obligation to assign
the Inventions or any rights relating thereto, to any employer, former employer or other entity; 

  

	 	9.2.3.	C-CHEM has not previously assigned, transferred, conveyed or otherwise encumbered its right, title and interest in the Patents, Inventions or the Know How, and C-CHEM has not granted any license, waiver, non-assertion
undertakings, options or other rights relating to the Patents, the Inventions or the Know How nor is it under any obligation to do so; 

  

	 	9.2.4.	 C-CHEM is the sole and exclusive owner of the Patents, the Inventions and the Know How, all of which are free and clear of any liens, charges and
encumbrances, and no other person, corporation or other private entity or governmental entity or subdivision thereof has, or to the best of C-CHEM’s 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 10 

	 	
knowledge, will have any claim of ownership or any rights with respect to the Patents and the Know How; 

 

	 	9.2.5.	to the best of C-CHEM’s knowledge, the practice of the Inventions disclosed in the Patents and Know How does not interfere with or infringe any intellectual property rights owned or possessed by any third
party [*]; 

  

	 	9.2.6.	there are no notices of infringement against C-CHEM, or claims, judgments or settlements against or owned by C-CHEM, or pending or threatened claims or litigation, relating to the Patents, Inventions or Know
How; 

  

	 	9.2.7.	to the best of C-CHEM’s knowledge, there are presently no third parties which are infringing the Patents; 

  

	 	9.2.8.	Schedule 1 lists all of the Patents in existence at the Commencement Date; 

  

	 	9.2.9.	all payments due in respect of the prosecution, maintenance and renewal of the Patents have been paid in full; 

  

	 	9.2.10.	C-CHEM does not have in its possession or control any compounds relating to Invention; 

  

	 	9.2.11.	C-CHEM has disclosed to Scynexis all reasonably relevant information concerning the Patents and Know How; 

  

	 	9.2.12.	C-CHEM does not own, or have a license or right to use, any intellectual property relating to cyclosporin or cyclosporin derivatives, other than the Patents and Know-How; 

 

	 	9.2.13.	attached hereto as Schedule 4 is a true, valid and complete copy of a resolution of the Board of Directors of C-CHEM, signed by Dr. Daniel Zimmermann, the sole Director of C-CHEM, approving this Agreement and the
transaction described herein; 

  

	 	9.2.14.	attached hereto as Schedule 5 is a true, valid and complete copy of a Shareholder resolution of C-CHEM, signed by Dr. Daniel Zimmermann, the sole shareholder of C-CHEM, approving this Agreement and the transaction
described herein; 

  

	 	9.2.15.	attached hereto as Schedule 6 is a true and complete copy of an extract of the Companies’ Register (Handelsregister) of C-CHEM setting forth the company details of C-CHEM; 

 

	 	9.2.16.	the [*] in accordance with its terms [*] described therein, and that [*] does not now have, and will not have in the future, any assignment, license, waiver, non-assertion, option or other right relating to the Patents,
the Inventions or the Know How: 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 11 

	 	9.2.17.	the [*], had the sole purpose to discuss possible collaborative strategies. No confidential information, documents or samples were [*]; and 

 

	 	9.2.18.	C-CHEM has not granted, pursuant to the [*], or any other agreement, commitment or undertaking; any assignment, license, waiver, non-assertion, option or other right relating to the Patents, the Inventions or the Know
How to bioLeads, nor is it under any obligation to do so in the future. 

  

	9.3.	In respect of Clause 9.2 above, Scynexis confirms that [*]. 

  

	9.4.	The parties acknowledge that C-CHEM will be responsible for paying to the Inventors and any other third parties any compensation that the Inventors or such third parties shall be owed in connection with making,
conceiving, or developing the Inventions, Patents, and Know-How and that Scynexis shall not have any responsibility therefor. Should the Inventors or any third party claim they are entitled to such compensation, Scynexis shall be entitled to pay
over any compensation due to C-CHEM pursuant to Clause 6 hereof into an escrow account maintained at a reputable bank or law firm, pending resolution of such claims. 

 

	10.	Limitation of Liability and Indemnity 

 10.1. Scynexis shall assume all risks associated with the
research, development, manufacture, use and supply of the Compounds and/or Products by Scynexis and its Affiliates and Licensees and shall be responsible for all third party claims relating to such Compounds and/or Products including, but not
limited to claims based on product liability laws. Scynexis shall fully indemnify, and at all times keep C-CHEM, its Affiliates and their Personnel fully indemnified, against any and all liability, damages, claims, proceedings and/or expenses
(including legal expenses and expert’s fees) arising out of or in connection with:- 
  

	 	10.1.1.	any research, development, manufacture, use, distribution or supply of the Compounds and/or the Products by Scynexis or its Affiliates or Licensees; and/or 

 

	 	10.1.2.	any possession or use by a third party of the Compounds and/or the Products manufactured and/or supplied by or on behalf of Scynexis, or its Affiliates or Licensees; and/or 

 

	 	10.1.3.	a breach of any of the warranties and representations given by Scynexis, pursuant to Clause 9.1. 

  

	10.2.	C-CHEM shall fully indemnify and at all times keep Scynexis, its Affiliates and their Personnel fully indemnified, against any and all liability, damages, claims, proceedings, expenses (including legal expenses and
expert’s fees) arising out of or in connection: 

  

	 	10.2.1.	with a breach of any of the warranties and representations given by C-CHEM pursuant to Clauses 9.1 and 9.2 and/or 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 12 

	 	10.2.2.	with any claims of the Inventors or any other third parties for any compensation that the Inventors or such third parties claim they are owed in connection with making, conceiving, or developing the Inventions, Patents,
and Know-How. 

 However, in no event shall [*] arising out of or in connection with this Agreement [*]. 

10.3. Where in this Agreement a party (the “Party Giving the Indemnity”) gives an indemnity to the other party (the “Party Receiving the
Indemnity”), such indemnity shall be subject to the following conditions:- 
  

	 	10.3.1.	the Party Receiving the Indemnity shall notify the Party Giving the Indemnity of any claim or action covered by the relevant indemnity (a “Claim”) within [*] of becoming aware of the Claim; 

 

	 	10.3.2.	the Claim does not arise as a consequence of any breach of this Agreement by the Party Receiving the Indemnity and/or from any negligence or misconduct by the Party Receiving the Indemnity; 

 

	 	10.3.3.	the Party Giving the Indemnity is given sole conduct of the defence and settlement of any Claim; 

  

	 	10.3.4.	the Party Receiving the Indemnity does not at any time prejudice the defence of the Claim; and 

  

	 	10.3.5.	the Party Receiving the Indemnity provides the Party Giving the Indemnity (at the cost of the Party Giving the Indemnity) with such assistance, documents, authority and information as the Party Giving the Indemnity may
reasonably require in relation to the Claim and the defence or settlement of the Claim. 

  

	10.4.	Neither party shall be liable for any punitive, special, consequential or indirect loss or damage arising out of this Agreement or any breach of it. 

 

	10.5.	In addition to the indemnification remedy described above, in the event that Scynexis is determined by a court, government agency, arbitrator or other body to be liable for any payments to the Inventors or any third
party for compensation in connection with the Inventions, Patents, and Know-How, Scynexis will be entitled to withhold a corresponding amount from any pending or future payments due to C-CHEM by Scynexis pursuant to Clause 6 hereof.

  

	11.	Infringements 

  

	11.1.	C-CHEM shall promptly notify Scynexis with such details as it has in its possession of any infringements of the Patents as and when it becomes aware of such infringement. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 13 

	11.2.	C-CHEM shall provide Scynexis with such assistance as Scynexis may reasonably request in connection with any proceedings against infringers of the Patents. Scynexis shall reimburse all C-CHEM’s reasonable
out-of-pocket expenses of providing such assistance, supported by the appropriate proof of payment. 

  

	12.	Maintenance of the Patents 

  

	12.1.	Subject to this Clause 12, Scynexis shall maintain the Patents in force until the end of their lifetime. 

  

	12.2.	If Scynexis does not wish to continue to pay the renewal fees or other fees in respect of a Patent, then Scynexis shall promptly notify C-CHEM of this intention at least [*] before the corresponding action must be
taken. 

  

	12.3.	If C-CHEM notifies Scynexis that it wishes to acquire the Patent notified to C-CHEM pursuant to Clause 12.2 then Scynexis shall promptly assign to C-CHEM all of Scynexis’ right, title and interest in the Patent and
C-CHEM shall grant to Scynexis a non-exclusive licence (together with the right to grant sub-licences) under the Patent to research, develop, manufacture, import, market, use, sell and supply products and to perform any other act that would infringe
the Patent were it not for this licence. This license shall be [*]. 

  

	12.4.	C-CHEM shall provide Scynexis with such assistance as Scynexis may reasonably request in connection with any proceedings where the validity of the Patents is at issue. Scynexis shall reimburse all of C-CHEM’s
reasonable out-of-pocket expenses of providing such assistance, supported by the appropriate proof of payment. 

  

	13.	Exploitation 

 Scynexis shall undertake reasonable commercial efforts to develop and
commercialise a Product having regard to the size and profitability of the potential market for the Product, the risks associated with the development of the Product and any adverse factors that may become apparent during the development of the
Product. 
  

	14.	Confidential Material 

  

	14.1.	In this Agreement, “Confidential Material” owned by Scynexis shall, subject to Clause 14.3, mean the Know How and all Information disclosed by Scynexis or any of its Affiliates to C-CHEM or any of its
Affiliates on or after the Commencement Date. 

  

	14.2.	In this Agreement, “Confidential Material” owned by C-CHEM shall, subject to Clause 14.3, mean all Information disclosed by C-CHEM or any of its Affiliates to Scynexis or any of its Affiliates on or after the
Commencement Date excluding the Know How. 

  

	14.3.	In this Agreement, “Confidential Material” shall not include any information or materials which the Holding Party can prove:- 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 14 

	 	14.3.1.	is or becomes public knowledge through no improper conduct on the part of the Holding Party, its Affiliates and/or their respective Personnel; 

 

	 	14.3.2.	is already lawfully possessed by the Holding Party and/or its Affiliates without any obligations of confidentiality or restrictions on use prior to the Holding Party first receiving it from the Owning Party provided
that this exception shall not apply in the case of the Know How and/or 

  

	 	14.3.3.	is obtained subsequently by the Holding Party and/or its Affiliates from a third party without any obligations of confidentiality and such third party is in lawful possession of such information or materials and not in
violation of any contractual or legal obligation to maintain the confidentiality of such information or materials. 

  

	14.4.	The Holding Party shall treat all Confidential Material owned by the other party as secret and confidential and shall not use, copy or disclose to any third party any Confidential Material owned by the other party
except that:- 

  

	 	14.4.1.	Scynexis may use and disclose Confidential Material owned by C-CHEM and/or its Affiliates as reasonably necessary to exploit the Patents and the Know How; 

 

	 	14.4.2.	C-CHEM may use and disclose Confidential Material owned by Scynexis as reasonably necessary to enforce its rights under this Agreement provided that C-CHEM shall not disclose information concerning development and/or
sales of the Products without the prior written consent of Scynexis. 

  

	 	14.4.3.	the Holding Party may disclose Confidential Material owned by the other party to those of its officers and employees and Affiliates to whom such disclosure is reasonably necessary (and only disclose that part of the
Confidential Material owned by the other party whose disclosure is reasonably necessary) provided that the Holding Party shall remain responsible for procuring that its officers and employees do not further disclose and/or use the Confidential
Material owned by the other party for any other purpose; and/or 

  

	 	14.4.4.	after giving written notice to the Owning Party, the Holding Party may disclose any part of the Confidential Material owned by the other party solely to the extent that it is legally required to do so pursuant to an
order of a court of competent jurisdiction or governmental authority provided that the Holding Party shall use its best endeavours to limit such disclosure and to provide the Owning Party with an opportunity to make representations to the relevant
court or governmental authority. 

  

	14.5.	 All documents, materials and other items (including items in electronic form), and any intellectual property rights therein, provided by the Owning
Party to the Holding Party 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 15 

	 	
containing Confidential Material shall remain the absolute property of the Owning Party. 

  

	14.6.	The Holding Party shall at all times maintain documents, materials and other items (including items in electronic form) containing Confidential Material owned by the other party and any copies thereof, in a secure
fashion by taking reasonable measures to protect them from theft and unauthorised copying, disclosure and without prejudice to the foregoing shall exercise at least the same degree of care to prevent unauthorized disclosure and/or use of the
Confidential Material owned by the other party as the Holding Party exercises in respect of its own confidential material of like importance. 

  

	14.7.	The Holding Party shall notify the Owning Party immediately if the Holding Party becomes aware of any unauthorised use or disclosure of, or any unauthorised access to or of any theft or loss of any copies of any
Confidential Material owned by the other party. 

  

	14.8.	The provisions of this Clause 14 shall continue for [*] and shall, for the avoidance of doubt, survive termination or expiry of this Agreement. 

 

	15.	Expiry and Termination 

  

	15.1.	Unless terminated earlier in accordance with the provisions of Clause 15.2 or 15.3 or 15.4, this Agreement shall expire when no Valid Claims remain. 

 

	15.2.	C-CHEM may terminate this Agreement forthwith by giving Scynexis immediate written notice of termination if an entry of a decree or order by a court of competent jurisdiction is made:- 

 

	 	15.2.1.	appointing a custodian, receiver, liquidator, assignee or trustee of Scynexis; or 

  

	 	15.2.2.	ordering the winding up or liquidation of the affairs of Scynexis. 

  

	15.3.	The Agreement can be terminated by Scynexis alone in its sole discretion, at any time, by [*] written notice to C-CHEM. 

  

	15.4.	In the event of any breach of any term or condition of this Agreement by either party, the non-breaching party shall give [*] written notice to the breaching party to correct such breach and the damages arisen
therefrom, along with a written explanation regarding the breach and such damages and how they should be corrected. In the event the breach and the damages arisen are not corrected within the [*] period, the non-breaching party shall have the right
to immediately terminate this Agreement by written notice of termination. 

  

	16.	Consequences Of Expiry Or Termination 

  

	16.1.	 On expiry of this Agreement, Scynexis shall have a fully paid-up, royalty free, world-wide, exclusive licence, and the right to grant sub-licences,
under the Know-How and Ancillary Rights to research, develop, manufacture, import, market, use, sell, and 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 16 

	 	
supply products and to perform any other act that would infringe the Know Flow and/or Ancillary Rights were it not for this licence. 

 

	16.2.	On expiry or termination of this Agreement for any reason:- 

  

	 	16.2.1.	Scynexis shall within [*] of the date of termination or expiry pay to C-CHEM all sums due to it under this Agreement in respect of the period up to and including the date of termination including any royalties payable
on Products sold prior to or on the date of termination; 

  

	 	16.2.2.	any rights or remedies of each of the parties arising from any breach of this Agreement shall continue to be enforceable; 

  

	 	16.2.3.	the following provisions shall continue in full force and effect: Clause 1 (Definitions), Clause 4 (Non-Exclusive License Grant), Clause 6 (Payment) in respect of Royalties payable pursuant to Clause 16.2.1, Clause 14
(Confidential Material), Clause 16 (Consequences of Expiry or Termination) and Clause 17 (General). 

  

	16.3.	On termination of this Agreement by C-CHEM pursuant to Clause 15.2 or 15.4, or by Scynexis pursuant to Clause 15.3, Scynexis shall promptly reassign the Patents, the Know How and the Ancillary Rights, and immediately
return the Documentation to C¬CHEM and: 

  

	 	16.3.1.	Scynexis shall, and shall procure that its Affiliates shall, forthwith cease all activities which would require a licence under the Patents save that Scynexis and its Affiliates shall be entitled to sell and dispose of
any stock of Products or Compounds in existence on or prior to the date of termination of the Agreement; and 

  

	 	16.3.2.	in the event that Scynexis has sublicensed the Patents to one or more Licensee(s), C-CHEM shall grant to each Licensee a licence on terms equivalent to the licence agreement between such Licensee and Scynexis, provided
however that the terms of the license between such Licensee and C-CHEM are not less favourable to C-CHEM than the licence terms contained in the present Agreement. 

 

	17.	General 

 Interpretation 

 

	17.1.	In this Agreement:- 

  

	 	17.1.1.	“including” means including without limitation; “include” and “includes” shall be construed accordingly. 

 

	 	17.1.2.	the headings are for convenience only and shall not affect the interpretation of this Agreement. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 17 

 Notices 
  

	17.2.	Any notice or other communication given under this Agreement shall be in writing in English and shall be:- 

  

	 	17.2.1.	delivered by hand or by courier ; or 

  

	 	17.2.2.	sent by pre-paid airmail; or 

  

	 	17.2.3.	sent by fax (confirmed by pre-paid airmail placed in the post on or on the day after the date of transmission); 

to the address or the fax number set out below or to such other address or fax number as may from time to time be notified to the other party
in writing. 
  

			
	SCYNEXIS, Inc.	  	C-CHEM AG
	Attn: General Counsel	  	Attn: Dr. Daniel Zimmermann
	3501-C TriCenter Boulevard	  	Bundesplatz 12
	Durham NC 27713	  	CH-6300 Zug
	United States of America	  	Switzerland
	Fax: 1 919 544 8697	  	Fax: 41 61 426 95 21

  

	17.3.	Any notice given under Clause 17.2 shall be deemed to have been received:- 

  

	 	17.3.1.	on the date of delivery if delivered by hand or by courier prior to 5:00 pm on a business day, otherwise on the next business day following the date of delivery; 

 

	 	17.3.2.	on the fourth business day from and including the day of posting in the case of pre-paid airmail; or 

  

	 	17.3.3.	on the next business day following the day of transmission in the case of facsimile (confirmed by pre-paid first class post/airmail as provided above). 

 

	17.4.	In Clause 17.3 business day shall mean a day that is not Saturday, Sunday and/or a public holiday in the country to which the notice is sent. 

Severability 
  

	17.5.	If any provision of this Agreement is declared by any judicial or other competent authority to be void, voidable, illegal or otherwise unenforceable then the remaining provisions of this Agreement shall continue in full
force and effect. The judicial or other competent authority making such determination shall have the power to limit, construe or reduce the duration, scope, activity and/or area of such provision, and/or delete specific words or phrases as necessary
to render, such provision enforceable. 

 Waiver 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 18 

	17.6.	Failure or delay by either party to exercise any right or remedy under this Agreement shall not be deemed to be a waiver of that right or remedy, or prevent it from exercising that or any other right or remedy on that
occasion or on any other occasion. 

 Entire Agreement 

 

	17.7.	This Agreement and the Assignment constitute the entire agreement and understanding of the parties relating to the subject matter of this Agreement and supersede all prior oral or written agreements, representations,
understandings or arrangements between the parties relating to the subject matter of this Agreement, including the Option Agreement. 

  

	17.8.	No provision of this Agreement shall operate to:- 

  

	 	17.8.1.	exclude any provision implied into this Agreement by law and which may not be excluded by law; or 

  

	 	17.8.2.	limit or exclude any liability, right or remedy to a greater extent than is permissible under law including in relation to (1) death or personal injury caused by the negligence of a party to this Agreement or
(2) fraudulent misrepresentation or deceit. 

  

	17.9.	No change shall be made to this Agreement except in writing in the English language signed by the duly authorised representatives or directors of both parties. 

Relationship of the Parties 
  

	17.10.	Nothing in this Agreement shall create, evidence or imply any agency, partnership or joint venture between the parties. 

  

	17.11.	Neither party shall act or describe itself as the agent of the other party nor shall either party have or represent that it has any authority to make commitments on behalf of the other. 

Assignment 
  

	17.12.	Neither party shall assign, delegate or transfer this Agreement, or assign, delegate, transfer, sub-contract or charge, any of its rights or obligations under hereunder, other than to an Affiliate or successor, without
the prior written consent of the other party, which consent shall not be unreasonably withheld. Notwithstanding the foregoing, Scynexis may assign, delegate, transfer, sub-contract or charge this Agreement, or any of its rights or obligations
relating thereto, in connection with the sale of all or substantially all of the assets to which this Agreement relates. 

Publicity 
  

	17.13.	 C-CHEM shall not and shall procure that its respective Personnel and Affiliates shall not, make any announcement, or comment upon, or originate any
publicity, or 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 19 

	 	
otherwise provide any information to any third party (other than its legal advisors and auditors) concerning this Agreement including the existence of this Agreement, the terms of this Agreement,
the performance of this Agreement and/or any dispute or disagreement relating to this Agreement, without the prior written consent of the Scynexis. 

Force Majeure 
  

	17.14.	If the performance by a party of its obligations under this Agreement is prevented, restricted, delayed or interfered with by any circumstances beyond the reasonable control of that party, its licensees, contractors and
subcontractors, then that party shall, upon giving prompt notice to the other party specifying the circumstances and obligations concerned, be excused from such performance to the extent of such prevention, restriction, delay or interference.

 Law and Jurisdiction 
  

	17.15.	This Agreement shall be governed by and construed and interpreted in accordance with the laws of the State of North Carolina (excluding its choice of law rules) and the parties irrevocably accept the exclusive
jurisdiction of the federal and state courts of the state of North Carolina in respect thereof. 

 AGREED by the parties through their
duly authorised representatives on the date written at the top of the first page of this Agreement:- 
  

									
	For and on behalf of C-CHEM AG	 		 	For and on behalf of SCYNEXIS, Inc.
					
	Signed:	 	 /s/ Daniel Zimmermann
	 		 	Signed:	 	 /s/ Brian Schwab

					
	Full Name:	 	 Daniel Zimmermann
	 		 	Full Name:	 	 Brian Schwab

					
	Title:	 	 Sole Board Member
	 		 	Title:	 	 Chief Licensing Officer and General Counsel

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 20 

 Schedule 1 

The Patents 
 [*]

  

							
	[*]	  	[*]	  	[*]	  	[*]

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 21 

 Schedule 1 

The Patents 
 [*]

  

							
	[*]	  	[*]	  	[*]	  	[*]

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 22 

 Schedule 2 

The Know How 
 [*]

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 23 

 Schedule 3 

Assignment of the Patents 

Dated 10 June 2005 

(1) C-CHEM AG 
 - and -

 (2) SCYNEXIS, Inc. 
  

 
 Patent
Assignment 
  
  

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 24 

 THIS ASSIGNMENT is made the 10th day of June 2005

 BETWEEN:- 
  

	(1)	SCYNEXIS, Inc. a corporation incorporated under the laws of Delaware having its principal place of business at 3501C Tricenter Boulevard, Durham, North Carolina, 27713, United States of America
(“Scynexis”); and 

  

	(2)	C-CHEM AG a company incorporated under the laws of Switzerland having its principal place of business at Bundesplatz 12, CH-6300 Zug, Switzerland (“C-CHEM”). 

BACKGROUND:- 
  

	(A)	C-CHEM is the owner of the Patents set out in the Appendix (the “Patents”). 

  

	(B)	C-CHEM is willing to assign the Patents to Scynexis, and Scynexis wishes to receive the-assignment of the Patents, in accordance with the provisions of this Assignment. 

THE PARTIES AGREE AS FOLLOWS:- 

Assignment 
  

	1.	C-CHEM hereby assigns to Scynexis irrevocably and absolutely with full title guarantee all right, title and interest in the Patents, including but not limited to:- 

 

	 	1.1	the right in relation to infringements of the Patents and any patents resulting from the Patents, to recover and take all such proceedings as may be necessary for the recovery of damages or otherwise, including, without
limitation, the right to recover damages for past infringements; 

  

	 	1.2	the right to apply for and the right to be granted patent, or other protection anywhere in the world in respect of the inventions disclosed in the Patents; 

 

	 	1.3	all rights to claim priority anywhere in the world on the basis of the Patents; and 

 the right
to apply for extensions, renewals and Supplementary Protection Certificates in respect of the Patents and any patents resulting from the Patents. 

Further Assurances 
  

	2.	C-CHEM shall free of charge, as and when requested by Scynexis, do all acts and execute all documents as may be reasonably necessary or desirable to give full effect to the provisions of this Assignment.

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 25 

 Law 
  

	3.	This Assignment shall be governed by the law of the State of North Carolina. 

 AGREED by the parties
through their duly authorised representatives on the date written at the top of the first page of this Agreement:- 
  

									
	For and on behalf of C-CHEM AG	 		 	For and on behalf of SCYNEXIS, Inc.
					
	Signed:	 	 /s/ Daniel Zimmermann
	 		 	Signed:	 	 /s/ Brian Schwab

					
	Full Name:	 	 Daniel Zimmermann
	 		 	Full Name:	 	 Brian Schwab

					
	Title:	 	 Sole Board Member
	 		 	Title:	 	 Chief Licensing Officer and General Counsel

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 26 

 Appendix 

The Patents 
 [*]

  

							
	[*]	  	[*]	  	[*]	  	[*]

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 27 

 [*] 
  

							
	[*]	  	[*]	  	[*]	  	[*]

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 28 

 Schedule 4 

C-CHEM AG Board of Directors Resolution 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 29 

									
		 	 Beschluss des Verwaltungsrats

der
 C-Chem AG

Bundesplatz 12, 6300 Zug
	  		 		 	 Resolution of Board of Directors

of
 C-Chem AG

Bundesplatz 12, 6300 Zug

	  

I.      
	 	  
 Traktanden:
	  		 	  

I.      
	 	  
 Agenda

					
		 	Verkauf und Uebertragung aller Patente der C-Chem AG (der „Verkauf”) gemaess dem Entwurf des “Agreement for the Assignment of Patents and Know How concerning Cyclosporin Derivatives” zwischen C-Chem AG and
Scynexis, Inc. P.O. Box 12878, Research Triangle Park, NC 27709-2878, USA, (der ,,Kaufvertrag”)	  		 		 	Sale and assignment of all patents of C-Chem AG (the “Sale”) pursuant to the draft of the Agreement for the Assignment of Patents and Know How concerning Cyclosporin Derivatives between C-Chem AG and Scynexis, Inc. P.O.
Box 12878, Research Triangle Park, NC 27709-2878, USA, (the “Sales Agreement”)
					
		 	Dem Verwaltungsrat liegt der Entwurf des Kaufvertrages vor.	  		 		 	The Board of Directors has been presented with the draft of the Sales Agreement
					
		 	Die ausserordentliche Generalversammlung der C-Chem AG vom 26. Mai 2005 hat den Kaufvertrag genehmigt und den Verwaltungsrat mit der Durchführung des Verkaufs beauftragt.	  		 		 	The extraordinary general assembly of the shareholders of C-Chem AG of 26th May 2005 has approved the Sales Agreement, and has authorized the Board of Directors to execute
the Sales transaction.
					
		 	Beantragt ist ein Beschluss des Verwaltungsrates der C-Chem AG, wonach der Verkauf und der Kaufvertrag zu genehmigen ist und Dr. Daniel Zimmermann mit der Durchführung des Verkaufs und der Unterzeichnung des Kaufvertrags
betraut wird.	  		 		 	Motion for a resolution by the Board of Directors of C-Chem AG that approves the sale and Sales Agreement, and that authorizes Dr. Daniel Zimmermann to consummate the Sale and sign the Sales Agreement.
	  

II.     
	 	  
 Beschluss
	  		 	  

II.     
	 	  
 Resolution

					
		 	Der Verwaltungsrat genehmigt den Verkauf und den Kaufvertrag und ermaechtigt Dr. Daniel Zimmermann mit der Durchführung des Verkaufs und der Unterzeichnung des Kaufvertrags der massgeblich dem beiliegenden Entwurf
entspricht.	  		 		 	The Board of Directors approves the Sale and the Sales Agreement, and that authorizes Dr. Daniel Zimmermann to consummate the Sale and sign the Sales Agreement that corresponds to the attached draft in all material
respects.

  

	26.	Mai 2005 

  

	
	 /s/ D. Zimmermann

	Dr. Daniel Zimmermann
	Einziges Mitglied des Verwaltungsrates
	(Sole Member of the Board of Directors)

 Beilage (Attachment): Entwurf Kaufvertrag Scynexis, Inc. (Draft of Sales Agreement Scynexis, Inc.) 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 29-A 

 Schedule 5 

C-CHEM AG Shareholder Resolution 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 30 

					
	 NOTARIELLES PROTOKOLL

der
 ausserordentlichen
Generalversammlung
 der

C-Chem AG
 Bundesplatz 12,
6300 Zug
 vom 26. Mai 2005
 in
Basel, Picassoplatz 8
	  		  	 MINUTES

of
 extraordinary general assembly
of shareholders
 of
 C-Chem
AG
 Bundesplatz 12, 63 00 Zug

of 26 May 2005
 in Basel,
Picassoplatz 8

	  
 Heute habe ich, Andreas Miescher, öffentlicher Notar des Kantons
Basel-Stadt, an der ausseror-dentlichen Generalversammlung der C-Chem AG, in Zug, abgehalten in meinem Büro, teilgenommen, und das nachfolgende Protokoll in öffentlicher Urkunde aufgenommen:
	  		  	  
 Today I, Andreas Miescher, Notary Public of the Canton of Basel-Stadt,
have been present at the extraordinary general assembly of Chem, in Zug, which took place in my office and kept the following minutes in a notarial act:

	  
 Anwesend:

Dr. Daniel Zimmermann (VR-Mitglied)
	  		  	  
 Present:

Dr. Daniel Zimmermann (Member of Board of Directors)

	  
 Dr. Daniel Zimmermann eröffnet die Versammlung und übernimmt
den Vorsitz. Der instrumentierende Notar wird mit der Führung des Protokolls betraut. Dr. Zimmermann stellt fest und der instrumentierende Notar bestaetigt, dass sämtliche Aktien der Gesellschaft wie folgt anwesend sind:
	  		  	  
 Dr. Daniel Zimmermann opens the general assembly and acts as
chairperson. The undersigned Notary is charged with keeping the minutes. Dr. Zimmermann determines and the undersigned Notary confirms that all shares of the company are present as follows:

  

											
	 Aktionär

(Shareholder)
	  	 Art

(Class of shares)
	  	Anzahl Aktien
(Number of
Shares)	 	  	in %	 
	 Dr. Daniel Zimmermann

als Aktionär / as shareholder
	  	 Inhaberaktien
 (Common bearer
shares)
	  	 	50	  	  	 	50	% 
	 Dr. Daniel Zimmermann

als Aktionär / as shareholder
	  	 Inhaber-Vorzugsaktien
 (Preferred bearer
shares)
	  	 	50	  	  	 	50	% 
		  		  	  
	  
	 	  	  
	  
	 
		  	 Total
	  	 	100	  	  	 	100	% 
		  		  	  
	  
	 	  	  
	  
	 

  

					
	Der Vorsitzende stellt entsprechend fest, dass sämtliche Aktionäre der C-Chem AG anwesend oder vertreten sind und die Versammlung damit als Universalversammlung gemäss Artikel 701 OR beschlussfähig ist.	  		  	The chairperson accordingly determines that all shareholders of C-Chem AG are present or represented, and that the assembly is able to make valid resolutions as a “Universal Assembly” pursuant to Article 701 of the Code of
Obligations.
	  
 Da gegen die den Anwesenden bekannte Traktandenliste sowie gegen die
obigen Feststellungen keine Einwendungen erhoben werden, werden die folgenden Traktanden behandelt:
	  		  	  
 Since no objections are raised against the agenda known to all present
and against the above determinations, the following agenda items will be discussed:

			
	 Verkauf und Uebertragung aller Patente der C-Chem AG (der „Verkauf”) gemaess dem Entwurf des “Agreement for the Assignment of Patents and
Know How concerning
	  		  	 Sale and assignment of all patents of C-Chem AG (the “Sale”) pursuant to the draft of the Agreement for the Assignment of Patents and Know How
concerning

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 30A 

					
	 Cyclosporin Derivatives” zwisehen C-Chem AG and Scynexis, Inc. P.O. Box 12878, Research Triangle Park, NC 27709-2878, USA, (der
„Kaufvertrag”)
	 		 	 Cyclosporin Derivatives between C-Chem AG and Scynexis, Inc. P.O. Box 12878, Research Triangle Park, NC 27709-2878, USA, (the “Sales
Agreement”)

	  
 Die Versammlung nimmt Kenntnis vom Entwurf des Kaufvertrages, der
vorgelegt wird und vom Antrag des Verwaltungsrates, den Verkauf und den Kaufvertrag zu genehmigen und den Verwaltungsrat mit der Durchführung des Geschäftes zu betrauen.
	 		 	  
 The assembly takes note of the draft of the Sales Agreement which is
being presented and of the motion of the Board of Directors to approve the Sale and the Sales Agreement, and to authorize the Board of Directors with the execution of the Sale transaction.

	  
 Die Versammlung genehmigt einstimmig den Verkauf und den Abschluss des
Kaufvertrages,der massgeblich dem beiliegendenEntwurf entspricht, und betraut den Verwaltungsrat mit der Durchführung des Geschäfts.
	 		 	  
 The Assembly approves unanimously the Sale and the Sales Agreement that
corresponds to the attached draft in all material respects, and authorizes the Board of Directors to consummate the Sale transaction.

	  
 Diverses
	 		 	  
 Various

			
	Keine weiteren Geschäfte.	 		 	No other business.
	  
 Nach Bchandlung sämtlicher Traktanden schliesst der Vorsitzende
die Versammlung. Er bestätigt, __ss während der ganzen Dauer sämtliche Aktien v__treten waren und dass kein Widerspruch gegen di__ Durchführung dieser Versammlung erhoben wu__e.
	 		 	  
 After discussion of and resolution on all agenda items, the chairperson
closes the assembly. He confirms that during the entire duration of the assembly, all shares have been represented, and that no objection was raised against the holding of the assembly.

 Urku__dlich dessen wurde dieses notarielle Protokoll nach Lesung und Genehmigung vom Vorsit__den. und von mir, dem
Notar, unter Beisetzung meines amtlichen. Siegels hiemach unterzeich__t. In Witness whereof these Notarial Minutes have been, after lecture and approval, signed by the Chairperson and by me, the notary public, who affixed the official seal.

 Basel, den 26 (sechsundzwanzigsten) Mai 2005 (zweitausendundfünf)/Basel, this 26th
(twenty-sixth) day of May 2005 (two thousand and five) 
  

	
	Der Vorsitzende (Chairperson)
	
	 /s/ D. Zimmermann

	Dr. Daniel Zimmermann
	Einziges Mitglied des Verwaltungs
	(Sole Member of the Board of Directors)
	
	Für das Protokoll (for the Minutes):
	
	 /s/ Andreas Miescher

	Andreas Miescher, Notar

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 30B 

 Schedule 6 

C-CHEM AG Extract from Companies Register 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 31 

  
 

 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 31A 

  
 

 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 31BEX-10.14

 Exhibit 10.14 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 RESEARCH SERVICES AGREEMENT 

This Research Services Agreement (this “Agreement”) is dated as of December 19, 2011 (the “Effective Date”),
and is by and between MERIAL Limited, a company limited by shares registered in England and Wales (registered number 3332751) with a registered office at P.O. Box 327, Sandringham House, Sandringham Avenue, Harlow Business Park, Harlow, Essex
CM19 5QA, England, and domesticated in Delaware, USA as MERIAL LLC, and having a place of business at 3239 Satellite Boulevard, Bldg. 500, Duluth, Georgia 30096 USA, on behalf of itself and any of its subsidiaries and/or Affiliates (hereinafter,
“MERIAL”), and SCYNEXIS, Inc., a Delaware corporation having a place of business at 3501 C Tricenter Boulevard, Durham, NC 27713 (hereinafter, “SCYNEXIS”). 

RECITALS 
 WHEREAS, it is
hereby contemplated that SCYNEXIS shall provide certain research services to MERIAL; and 
 WHEREAS, SCYNEXIS intends to provide such
research services to MERIAL. 
 NOW, THEREFORE, in consideration of the mutual covenants and obligations hereinafter set forth, the parties
hereto hereby agree as follows: 
  

	1.	Definitions. 

 “Affiliate” shall mean any existing or future company
directly or indirectly controlling, controlled by or under common control with a Party, where control means the direct or indirect ownership of at least fifty percent (50 %) of the capital stock of the company or the power to exercise at least fifty
percent (50 %) of the voting rights of the company, or the power to determine the policy of the company, provided such company agrees to be bound by the terms of this Agreement. 

“Agreement Intellectual Property” shall mean Intellectual Property related to or resulting from SCYNEXIS’s performance
pursuant to this Agreement, including the Compounds. 
 “[*]” shall mean any [*], or [*] that [*] and/or [*], including but not
limited to, [*]. 
 “Change of Control” shall mean the acquisition by any natural person or business entity, other than
MERIAL, Sanofi, or one of their Affiliates, directly or indirectly, of shares representing in the aggregate more than [*] percent of the aggregate voting power represented by the issued and outstanding capital stock of SCYNEXIS; or a merger,
consolidation or reorganization involving SCYNEXIS (other than with MERIAL, Sanofi, or one of their Affiliates); or the sale or disposition of all or substantially all of the assets of SCYNEXIS to any person (other than to MERIAL, Sanofi, or one of
their Affiliates). 

  

					
	12/19/2011	 	CONFIDENTIAL	  	Page 1

 “Compound” shall mean any chemical compound that has been screened, tested or
synthesized by SCYNEXIS under this Agreement and: (1) whose structure is [*], (2) the property(-ies) or activity(-ies) of which [*], or (3) that is [*] or [*] but is not [*] or [*]. 

“Compound Family” shall mean the compounds that are [*] a Compound. 

“Confidential Information” shall mean all proprietary or confidential information, knowledge, property, or data of the
disclosing party or its Affiliates that does not otherwise qualify as a Trade Secret, including, but not limited to, the procedures, techniques, and business strategies of the disclosing party or its Affiliates or clients, lists or names of clients,
customers or partners of the disclosing party or its Affiliates, lists or names of employees of the disclosing party or its Affiliates, or any other confidential or proprietary information of the disclosing party or its Affiliates that does not
otherwise qualify as a Trade Secret. 
 “FTE” shall mean one person who is a SCYNEXIS employee and is engaged on a full-time
basis (i.e., at least 40 hours per week) on the Services Team. For the sake of clarity, a FTE is one named person and is not a “full-time equivalent” of 40 hours of work provided by more than one SCYNEXIS employee. 

“Information” shall mean both Confidential Information and Trade Secrets. 

“Intellectual Property” shall mean any form of intellectual property including, without limitation, all written materials and
other works which may be subject to copyright, trade secrets, all patentable and unpatentable inventions, ideas, know-how, improvements, concepts, discoveries, know-how, research materials, technical information, test data, product efficacy and
safety data, existing or pending Patents, and trademarks. 
 “Losses” shall mean any liability, damage, loss, penalties,
fines, claims, costs or expense (including reasonable attorney fees). 
 “Materials” shall mean any materials or compounds
provided by MERIAL to SCYNEXIS or created or prepared by SCYNEXIS for use in the Scope of Services and shall include progeny, portions and derivatives of such Material and any associated know-how and data provided by MERIAL or created during the
provision of the Services. 
 “Patents” shall mean patent applications and granted patents including but not limited to
divisions, reissues, re-examinations, continuations, continuations in part, renewals, extensions, utility models and supplementary protection certificates. 

“RSC” (Research Steering Committee) shall have the meaning given in Section 3. 

“Screening” shall mean the determination of any property of a chemical compound, including, but not limited to, physical,
biological or phenotypic properties. 
 “Services” shall have the meaning set forth in Section 2 below. 

“Services Team” shall mean the SCYNEXIS employees identified in Exhibit XXX. 

  

					
	12/19/2011	 	CONFIDENTIAL	  	 Page
 2

 [*] = Certain confidential information contained in this document, marked by brackets, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 “Term” shall mean the three (3) year period beginning on January 1,
2012 and ending on December 31, 2014. 
 “Trade Secrets” shall include, except as otherwise provided by applicable law,
any information of the disclosing party or its Affiliates, without regard to form, including, but not limited to, technical or non-technical data, formulae, patterns, compilations, programs, devices, methods, techniques, drawings, processes,
financial data, financial plans, product plans, or lists of actual or potential customers or suppliers which is generally not known by or available to the public and which information: (i) derives economic value, actual or potential, from not
being generally known to, and not being readily ascertainable by proper means by, other persons who can obtain economic value from its disclosure or use and (ii) is the subject of efforts by the disclosing party that are reasonable under the
circumstances to maintain its secrecy. 
  

	2.	Scope of Work. 

  

	 	2.1.	SCYNEXIS will perform the research services for MERIAL as described in Exhibit 1 attached hereto (“Services”) at the staffing levels (in terms of the qualifications, background and respective time
commitments for each project member (“Project Team”)) set forth therein. MERIAL reserves the right to modify the scope and/or type of Services, the target organisms, and the staffing levels (including the ratio of biologist to chemist) of
the Project Team upon [*] notice. If any such change will result in an increase in the Fees, SCYNEXIS will notify MERIAL promptly, and MERIAL must approve any increase prior to SCYNEXIS implementing the change. For the avoidance of doubt, any such
modification shall not decrease the amount of the compensation payable to SCYNEXIS pursuant to Section 5 below. MERIAL also reserves the right to stop research into a particular Compound or series of Compounds. 

 

	 	2.2.	MERIAL shall be responsible for managing, engaging and paying for third parties used to provide complimentary services to the Services provided by SCYNEXIS. SCYNEXIS shall use its best efforts to coordinate such
complimentary services with the Services, including, but not limited to, reviewing and developing with Merial the scope of work desired to be performed by third parties, sending and receiving compounds, transferring data, experimental procedures,
and protocols to third parties, receiving and analyzing data from third parties, and participating in meetings (in person and telephonic) with such third parties, as reasonably requested by MERIAL, provided that SCYNEXIS’ corresponding out of
pocket travel expenses preapproved in writing by MERIAL shall be reimbursed by MERIAL. 

  

	3	Research Steering Committee 

  

	 	3.1.	The Parties hereby establish a committee (“Research Steering Committee” or “RSC”) comprised of four (4) permanent members, with two (2) representatives appointed by each Party. A Party may
designate or change one or more of its representatives on the RSC at any time upon written notice to the other Parties. The RSC may invite additional guests to specific RSC meetings, on an “as needed”, by invitation basis, provided that
all such guests will be required to enter into corresponding confidentiality agreements. The patent attorney with primary responsibility for Patent filings on Compounds also may attend the RSC meetings as a nonvoting member. 

  

					
	12/19/2011	 	CONFIDENTIAL	  	 Page
 3

 [*] = Certain confidential information contained in this document, marked by brackets, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	3.2	The Research Steering Committee shall: 

  

	 	(i)	discuss chemical structures to be investigated (synthesized or acquired) for screening; 

  

	 	(ii)	review results of Services; and 

  

	 	(iii)	review the portfolio of Compounds and determine priorities for the up-coming three months. 

  

	 	3.3	The RSC shall meet at least [*] a year in person at either SCYNEXIS or MERIAL facilities or by video conference or telephone. Each party shall bear its own expenses associated with these meetings. To constitute a quorum
at least two representatives for each Party must attend. If a designated representative of a Party cannot attend any meeting of the RSC, such Party may designate a different representative for that meeting upon giving prior notice to the other
Party. This substitute representative shall have the same rights as the Party’s appointed member to the RSC. The Parties shall coordinate and cooperate with each in good faith in managing the Services and use good faith to reach mutually
agreeable decisions. Any disagreements between the Parties shall be equitably reduced by good faith negotiations between MERIAL and SCYNEXIS. In the event the members of the RSC cannot reach agreement, [*]. Minutes of the RSC meetings shall be [*].

  

	4.	Material. 

  

	 	4.1	SCYNEXIS shall use the Materials solely for the purpose set forth in this Agreement and for no other purpose. SCYNEXIS may not transfer the Material to third parties without the express written consent of MERIAL. The
transfer of the Material to SCYNEXIS shall not be construed as a sale of the Material by MERIAL to SCYNEXIS. 

  

	 	4.2	SCYNEXIS shall use the Material in compliance with all applicable statutes, regulations, and guidelines. 

  

	 	4.3	Nothing in this Agreement grants SCYNEXIS any rights under any patents, patent applications, or other property rights of MERIAL, nor any rights to use any tools, techniques, or material derived from, or associated with
the Material, for additional research, profit-making, commercial activities, or any other purpose not identified hereunder. ALL MATERIALS ARE SUPPLIED AS IS, WITHOUT ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER
WARRANTY, EXPRESS OR IMPLIED. The Material supplied hereunder by MERIAL to SCYNEXIS shall remain the property of MERIAL, and SCYNEXIS shall, at MERIAL’s option, dispose of any unused Material and its derivatives or return it to MERIAL.

  

	 	4.4	SCYNEXIS further represents that it has adequate systems, procedures and personnel to review and oversee arrangements for the receipt, handling, storage, use and disposal of the Material and that it will ensure that all
persons involved in receiving, handling, storing, using or disposing of the Material are adequately qualified by training and experience to do so safely and legally. 

  

					
	12/19/2011	 	CONFIDENTIAL	  	 Page
 4

 [*] = Certain confidential information contained in this document, marked by brackets, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	5.	Compensation. 

 MERIAL will pay SCYNEXIS the amount specified in Exhibit 2
attached hereto according to the terms therein. These fees shall remain fixed for the Term of the Agreement and may not be decreased. Any changes made to the scope of the Services or the composition of the Project Team which increase these Fees must
be approved in advance in writing by MERIAL and SCYNEXIS. 
  

	6.	Laboratory Visits and Inspections. 

  

	 	6.1	MERIAL’s representatives shall have the option to visit SCYNEXIS’s laboratory during regular business hours to observe the progress of the Services, discuss the Services, and to review the scientific records
relating to the Services. SCYNEXIS shall assist MERIAL in scheduling such visits. All such visits shall be scheduled upon reasonable notice by MERIAL. 

  

	 	6.2	SCYNEXIS agrees to provide MERIAL with prompt, and advance, if possible, notice of any GLP, GCP or GMP inspection by a regulatory agency of SCYNEXIS where such inspection either directly or indirectly relates to the
Services provided under this Agreement. For purposes of this provision, “prompt” shall mean as soon as practicable, but in no case more than [*] from receipt of the notice by SCYNEXIS. 

 

	 	6.3	SCYNEXIS agrees that MERIAL shall have the right, from time to time, upon written notice to SCYNEXIS, to conduct an investigation and audit of SCYNEXIS’s books, records and accounts to verify compliance with this
Agreement. SCYNEXIS agrees to cooperate fully with such investigation, the scope, method, nature and duration of which shall be at the sole reasonable discretion of MERIAL. 

 

	7.	Work Product. 

 All reports will be prepared in English and in SCYNEXIS’s standard
format unless otherwise specified in the Scope of Services. SCYNEXIS will provide the data management system to store and manage all screening data (HEOS). MERIAL will have title to, and be responsible for, archival of all raw data, documentation,
records, protocols, specimens and final reports generated as a result of this Agreement, except for SCYNEXIS’s procedural manuals, development processes, facility-specific data, personnel data, and SCYNEXIS-developed know-how, technology and
software for which title and archival responsibilities shall remain with SCYNEXIS. If at any time MERIAL requests that data from the Services be transferred to MERIAL data management systems, SCYNEXIS will use all reasonable efforts to effectuate
this transfer at no additional cost to MERIAL. 
  

	8.	Manner of Performance. 

  

	 	8.1	 Except as authorized in this Section 8.1, for the term of the Agreement, SCYNEXIS shall [*] under this Agreement and [*] and [*] in this
Agreement [*] for providing the Services. [*] shall include, but not be limited to, [*], and [*] and [*]. For the sake of clarity, barring any change arising from [*] or [*], [*] will [*] and shall [*] during the Term of the Agreement. In the event
[*] is [*] but is not [*] or in the event [*] changes over the Term, as agreed in a writing signed by both Parties, and as a result of those changes [*] no 

  

					
	12/19/2011	 	CONFIDENTIAL	  	 Page
 5

 [*] = Certain confidential information contained in this document, marked by brackets, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
longer [*], [*] would not be or would no longer be (as the case may be) subject to [*] set forth herein (but would continue to be subject to [*] set forth in in this Agreement to the extent [*]).
SCYNEXIS shall set-up and enforce appropriate confidentiality measures and firewalls respecting its activities under this Agreement to ensure that they are kept separate from the other activities of SCYNEXIS. Such steps shall include, without
limitation, written secrecy obligations with terms no less restrictive than obligations set forth herein for all employees, contractors and contributors under this Agreement, regardless of whether such individuals are third parties or employees of
SCYNEXIS. SCYNEXIS shall also establish a security system for the facilities used to perform the Services which restricts access to those facilities to only those SCYNEXIS employees who (1) are providing the Services and have been approved by
MERIAL in writing or (2) maintain the facilities or equipment. Such system must be capable of recording the names and times of every person who enters and exits the facilities. SCYNEXIS must retain the records from the security system for the
duration of the Term and for [*] thereafter. For the avoidance of doubt, [*] set forth in this Agreement are not intended to, and do not, modify or amend any of SCYNEXIS’s obligations under the Collaboration Agreement, dated July 15, 2005,
which by the terms of such Collaboration Agreement, survive termination of that agreement. 

  

	 	8.2	SCYNEXIS will not make available, use for any purpose other than rendering the Services, or disclose Information, Materials, Agreement Intellectual Property, or Compounds or their chemical structures to any third
party (other than subcontractors pre-approved by MERIAL and only to the extent MERIAL permits in writing). 

  

	 	8.3	SCYNEXIS represents that it, and each of its employees, and any third party engaged by SCYNEXIS, who perform, directly or indirectly, the Services, has the requisite expertise, ability and legal right to render
the Services and that it can and will perform the Services in an efficient manner in accordance with prevailing industry standards and practices for the performance of similar services and with the Scope of Services. 

 

	 	8.4	SCYNEXIS will abide by all federal, state, and local laws, rules and regulations that apply to the performance of the Services, including the requirements of the U.S. Foreign Corrupt Practices Act
(“FCPA”) and any other applicable anti-corruption national or international laws and regulations, as well as the policies of MERIAL. 

  

	 	8.5	SCYNEXIS makes no representation or warranty that the Services will not violate or infringe upon any presently issued United States patent, copyright, trade secret or other contractual, employment or
confidentiality right of a third party. 

  

	 	8.6	 SCYNEXIS and MERIAL agree that all transactions will be accurately reflected in their books and records, and that no funds or other assets will
be paid directly or indirectly to government officials (or persons acting on their behalf) for the purpose of influencing government decisions or actions. No payments or transfer of value shall be made which have the purpose or effect of public or
commercial bribery, acceptance of or acquiescence in extortion, 

  

					
	12/19/2011	 	CONFIDENTIAL	  	 Page
 6

 [*] = Certain confidential information contained in this document, marked by brackets, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
kickbacks or other unlawful or improper means of obtaining or retaining business. 

  

	 	8.7	SCYNEXIS agrees to maintain anti-bribery policies and procedures as are appropriate for its business. 

  

	 	8.8	SCYNEXIS also hereby represents and warrants to MERIAL that no ownership interest, direct or indirect, in the contractual relationship established by this Agreement, is held or controlled by or for the benefit of
any foreign political party or foreign official. 

  

	 	8.9	SCYNEXIS agrees that should it learn or have reason to know of: (i) any payment, offer, or agreement to make a payment to a foreign government official or political party for the purpose of obtaining
retaining business or securing any improper advantage for MERIAL under this Agreement or otherwise, or (ii) any other development during the term of this Agreement that in any way makes inaccurate or incomplete the representations, warranties
and certifications of SCYNEXIS hereunder given or made as of the date hereof or at any time during the term of this Agreement related to MERIAL ethics, anti-bribery policy, and related policies and procedures, SCYNEXIS will immediately advise MERIAL
in writing of such knowledge or suspicion and the entire basis known to SCYNEXIS therefore. 

  

	 	8.10	In the event that MERIAL believes, in good faith, that SCYNEXIS has acted in any way that may subject MERIAL to liability under anti-corruption laws, MERIAL shall have the unilateral right, exercisable
immediately upon written notice to SCYNEXIS, to terminate this Agreement. 

  

	 	8.11	No employee of MERIAL will have authority to give any direction, written or oral, relating to the making of any commitment by SCYNEXIS or its agents to any third party in violation of the terms of this Section 8.

  

	9.	Equal Opportunity Employer. 

 Each party affirms that it is an equal opportunity employer
and shall comply with all applicable federal, state and local laws and regulations. Neither party shall discriminate because of race, color, religion, sex, age, national origin, disability, or status as a veteran, or any other reason as defined and
prohibited by applicable law, in the recruitment, selection, training, utilization, promotion, termination or other employment-related activities concerning the Services employees. As a condition of this Agreement, SCYNEXIS agrees to maintain a
working environment free from all forms of harassment, including race, color, religion, sex, age, national origin, disability, or status as a veteran, or any other reason as defined and prohibited by applicable law. 

 

	10.	Term and Termination. 

  

	 	10.1	The Agreement shall commence on January 1, 2012, and shall remain in full force and effect (unless otherwise terminated) during the Term. 

 

	 	10.2	Either Party may terminate this Agreement in the event of breach of material obligation by the other party if such breach remains uncured after [*] written notice from the non-breaching party to the breaching
party. 

  

					
	12/19/2011	 	CONFIDENTIAL	  	 Page
 7

 [*] = Certain confidential information contained in this document, marked by brackets, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	10.3	Either party may terminate this Agreement immediately by written notice if the other party makes an assignment for the benefit of creditors, becomes subject to a bankruptcy proceeding, is subject to the
appointment of a receiver, or admits in writing its inability to pay its debts as they become due. 

  

	 	10.4	If SCYNEXIS experiences a Change of Control in which [*], by no later than [*] thereafter, SCYNEXIS shall either: (i) [*] that is [*] and [*] and [*]; (ii) [*] (e.g., [*]) [*]; or (iii) where [*]
that [*] as a result of the Change of Control, [*] disregard the Change of Control and to continue this Agreement as if the Change of Control had not occurred. [*] any scenario described in clause (i), (ii) or (iii). If [*] by the end of the
[*], [*]. For the avoidance of doubt, SCYNEXIS hereby confirms that during the [*] period referred to above, it will fully respect its commitments pursuant to this Agreement, including those relating to the use and disclosure of confidential
information. For the sake of clarity, under no circumstance [*] in any manner [*] at any time. 

  

	 	10.5	At termination or expiration of the Agreement for any reason, upon MERIAL’s written request, SCYNEXIS will transfer to MERIAL all Agreement Intellectual Property, including all samples of the Compounds, and
all documents or data related to, or generated in the course of performing, the Services, including but not limited to data stored in HEOS, reports, files, presentations, protocols, specimens, records, parasites, and any other work product.

  

	 	10.6	The following provisions shall survive the expiration or termination of this Agreement: Sections 1, 4, 7, 8.2-8.6, 8.9, 10, 11, 12, 14-16, 17.3, and 21-23. 

 

	 	10.7.6	Expiration or termination of this Agreement shall not affect the rights, obligations or liabilities of the Parties accruing prior to such expiration or termination. 

 

	11.	Limitation of Liability. 

 EXCEPT FOR A BREACH OF OBLIGATIONS RELATING TO CONFIDENTIALITY
OR INTELLECTUAL RIGHTS UNDER THIS AGREEMENT OR AS PART OF THEIR INDEMNIFICATION OBLIGATIONS UNDER THIS AGREEMENT, NEITHER PARTY SHALL BE ENTITLED TO, NOR BE RESPONSIBLE FOR, ANY INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL LOSSES OR DAMAGES
ARISING IN CONNECTION WITH A DEFAULT OR BREACH OF THEIR RESPECTIVE OBLIGATIONS UNDER THIS AGREEMENT. 
  

	12.	Exclusivity. 

 During the Term and for a period of [*] after termination of this
Agreement for any reason, SCYNEXIS shall not, directly or indirectly, [*] on the [*]. For so long as the Agreement Intellectual Property remains protected under any law, statute, or regulation, including, but not limited to, patent and trade secrets
protection laws, SCYNEXIS may not use the Agreement Intellectual Property for any purpose other than to render the Services during the Term of the Agreement. For the avoidance of doubt, nothing in this Section 12 is intended to modify the
Parties’ obligations under Section 15 or 16. 

  

					
	12/19/2011	 	CONFIDENTIAL	  	 Page
 8

 [*] = Certain confidential information contained in this document, marked by brackets, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	13.	Independent Contractor. 

 SCYNEXIS will be an independent contractor, and no employment,
agency, partnership, or joint venture relationship between the parties or their respective employees, either express or implied, shall be created by this Agreement. MERIAL will not be responsible for SCYNEXIS’s acts while performing the
Services, whether on SCYNEXIS’s premises, MERIAL’s premises or elsewhere, and SCYNEXIS shall have no authority to speak for, represent, or obligate MERIAL except as expressly authorized in writing by MERIAL. 

 

	14.	Indemnification. 

  

	 	14.1	MERIAL’s Indemnity 

 Except to the extent caused by SCYNEXIS’s negligence or
willful misconduct, MERIAL hereby agrees to indemnify and hold SCYNEXIS (and its directors, officers, employees, agents, successors and assigns) harmless from and against any and all Losses arising out of or connected with a third party claim
relating to: 
  

	 	i)	to any breach by MERIAL of any of its representations and warranties contained in this Agreement or 

  

	 	ii)	any claim of infringement of any Intellectual Property of third parties arising from or relating to performance of the Services; or 

  

	 	iii)	the use by MERIAL, or its Affiliates, sublicensees, employees, agents and consultants of the compounds delivered by SCYNEXIS hereunder, except to the extent such Losses are attributable to a breach by SCYNEXIS of its
representations and warranties in this Agreement or the negligent acts or omissions or willful misconduct in SCYNEXIS’s performance of the Services. MERIAL shall not be liable under this Section 14 for any settlement effected without its
consent of any claim, litigation or proceeding in respect of which indemnity may be sought hereunder, which consent shall not be unreasonably withheld. 

  

	 	14.2	MERIAL will not be responsible for, or indemnify SCYNEXIS for, any acts performed by SCYNEXIS, or any one working for SCYNEXIS, outside the scope of the Services, whether on SCYNEXIS’s premises,
MERIAL’s premises, or elsewhere. 

  

	 	14.3	SCYNEXIS’s Indemnity 

 Except to the extent caused by MERIAL’s
negligence or willful misconduct, SCYNEXIS hereby agrees to indemnify and hold MERIAL (and its Affiliates and respective directors, officers, employees, agents, successors and assigns) harmless from and against any and all Losses arising out of or
connected with a third party claim relating to: 
  

	 	i)	any breach by SCYNEXIS of its representations and warranties in this Agreement; 

  

					
	12/19/2011	 	CONFIDENTIAL	  	 Page
 9

 [*] = Certain confidential information contained in this document, marked by brackets, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	ii)	SCYNEXIS’ negligent acts or omissions or willful misconduct in the performance of the services hereunder or the synthesis, labeling or handling of the Compounds provided to MERIAL or the synthesis or handling of
Compounds acquired from third parties. SCYNEXIS shall not be liable under this Section 14 for any settlement effected without its consent of any claim, litigation or proceeding in respect of which indemnity may be sought hereunder, which
consent shall not be unreasonably withheld. 

  

	 	14.4	The indemnified party shall notify the indemnifying party promptly in writing of any such claim, and the indemnifying party shall have the sole control of the defense and all related settlement negotiations
(unless any settlement involves anything other than the payment of money exclusively by the indemnifying party). The indemnified party shall provide the indemnifying party with reasonably requested assistance, information, and authority to perform
the above. 

  

	15.	Confidentiality. 

  

	 	15.1.	Obligations. Each receiving party agrees that it shall: 

  

	 	i)	maintain all Information in strict confidence, except that the receiving party may disclose or permit the disclosure of any Information to its, and its Affiliates’ directors, officers, employees,
consultants, approved subcontractors, and advisors who are obligated to maintain the confidential nature of such Information and who need to know such Information for the purposes set forth in this Agreement; 

 

	 	ii)	use all Information solely for the purposes set forth in, or as permitted by, this Agreement; 

  

	 	iii)	allow its directors, officers, employees, consultants, approved subcontractors, and advisors to reproduce the Information only to the extent necessary to effect the purposes set forth in this Agreement, with all
such reproductions being considered Information; 

  

	 	iv)	cause any consultant or advisor engaged by the receiving party to whom Information is disclosed to execute a confidentiality and nondisclosure agreement in form and substance reasonably acceptable to the
disclosing party. 

  

	 	15.2	Exceptions 

 The obligations of a receiving party under this Section 15 shall not
apply to the extent that the receiving party can demonstrate that the corresponding Information: 
  

	 	i)	was in the public domain prior to the time of its disclosure under this Agreement; 

  

	 	ii)	 entered the public domain after the time of its disclosure under this Agreement through means other than an unauthorized disclosure

  

					
	12/19/2011	 	CONFIDENTIAL	  	 Page
 10

 [*] = Certain confidential information contained in this document, marked by brackets, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
resulting from an act or omission by the receiving party or its employees, agents or representatives; 

  

	 	iii)	was as shown by written proof independently developed or discovered by employees of the receiving party without use of or access to the Information; 

 

	 	iv)	is or was disclosed lawfully to the receiving party at any time, whether prior to or after the time of its disclosure under this Agreement, by a third party having no fiduciary relationship with the disclosing
party and having no obligation of confidentiality to the disclosing party with respect to such Information; or 

  

	 	v)	is required to be disclosed to comply with applicable laws or regulations (such as disclosure to the United States Environmental Protection Agency or the USPTO or to their foreign equivalents), or to comply with
a court or administrative order, provided that the disclosing party receives prior written notice as soon as possible after such court or administrative order is served on the receiving party and that the receiving party takes all reasonable and
lawful actions to obtain confidential treatment for such disclosure and, if possible, to minimize the extent of such disclosure; or 

  

	 	vi)	is disclosed by MERIAL to governmental, other regulatory agencies, or third parties in compliance with this Agreement in order to gain governmental approval, to perform studies, to conduct trials or to market
products, but such disclosure may only be to the extent reasonably necessary. 

  

	 	15.3	Return of Information 

 Except for Information the rights to which have been granted to
a receiving party, upon the termination of this Agreement, at the request of the disclosing party, the receiving party shall destroy all originals, copies, extracts and summaries of documents, materials, and other tangible manifestations of
Information in the possession or control of the receiving party, except that the receiving party may retain one copy of the Information in the possession of its in house or outside legal counsel solely for the purpose of monitoring its obligations
under this Agreement. 
  

	 	15.4	Publications 

 MERIAL acknowledges SCYNEXIS’s interest in publishing the results to
obtain recognition within the scientific community and to advance the state of scientific knowledge. Both Parties recognize their mutual interest in obtaining valid patent protection and in protecting business interests and trade secret information.
Consequently, SCYNEXIS and its employees, agents, consultants, representatives, subsidiaries, and successors wishing to make a publication shall submit its request for publication to MERIAL in writing, along a copy of the proposed written
publication or an outline of an oral disclosure, at least [*] prior to submission for publication or presentation for approval by MERIAL, which approval shall not be unreasonably withheld. SCYNEXIS shall make modifications to the publication
requested by MERIAL for patent 

  

					
	12/19/2011	 	CONFIDENTIAL	  	 Page
 11

 [*] = Certain confidential information contained in this document, marked by brackets, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
reasons, trade secret reasons, regulatory reasons or other business reasons and to delay publication or presentation for a reasonable period in order to protect Information, know-how and
patentable information. Once a publication has been published or presented in accordance with this Section, SCYNEXIS does not need to present the information in such publication again to MERIAL prior to being used in another publication. 

 

	 	15.5	Disclosure of this Agreement and Publicity 

 Neither Party shall reveal the name of the
other Party or the existence or terms of this Agreement without the prior written approval of the other Party, except to the extent required by applicable securities laws or other applicable law or regulation or in connection with a transaction
involving the offer or sale of equity or debt instruments, subject to the Disclosing Party entering into a confidentiality agreement with the other party(-ies) with confidentiality obligations no less stringent then the obligations set forth herein.

  

	 	15.6	Survival of Obligations 

 With respect to each disclosure of Trade Secrets, the
obligations created herein shall survive until such time that it can be demonstrated that the Trade Secret has become publicly available in the public domain. With respect to each disclosure of Confidential Information, the obligations created
herein shall survive for [*] from termination or expiration of this Agreement, whichever date is later. 
  

	16.	Intellectual Property Rights. 

  

	 	16.1	The background technology of each Party shall remain the sole and unencumbered property of such Party. Except as explicitly stated in this Agreement, neither Party shall acquire any rights to the background
technology of the other Party. 

  

	 	16.2	SCYNEXIS agrees that SCYNEXIS is performing the Services as work for hire and that all Agreement Intellectual Property shall be the sole and entire property of MERIAL, subject to MERIAL’s obligations to
third parties. SCYNEXIS hereby assigns all rights, title, and interest to any copyrights and any Agreement Intellectual Property. 

  

	 	16.3	SCYNEXIS agrees to disclose promptly all Agreement Intellectual Property to MERIAL, without royalty or any other consideration, and in any event, prior to the termination of this Agreement. 

 

	 	16.4	 MERIAL will be responsible for performing all freedom-to-operate reviews relating to the Services and for filing and prosecuting any Patents
resulting from the Services. SCYNEXIS will provide MERIAL with any relevant information related to Compounds, such as chemical structure, so that MERIAL can generate freedom-to-operate opinions as soon as practically possible. SCYNEXIS also will
supply required information for Patent filings. SCYNEXIS agrees to (a) execute any document of assignment or title to transfer and perfect title to Agreement Intellectual Property as MERIAL may, from time to time, deem appropriate, and
(b) cooperate fully in freedom to operate reviews and in obtaining whatever protection for Agreement 

  

					
	12/19/2011	 	CONFIDENTIAL	  	 Page
 12

 [*] = Certain confidential information contained in this document, marked by brackets, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
Intellectual Property, including Patent rights, MERIAL shall require. The obligations of SCYNEXIS under this Section 16 to execute title documents and cooperate in matters of title
protection shall not terminate upon the termination of this Agreement, but rather, shall continue in effect thereafter with respect to all such obligations; provided, however, that MERIAL shall reimburse SCYNEXIS for all out-of-pocket expenses
incurred by SCYNEXIS in performing services under this Section 16 requested by MERIAL after termination of this Agreement. 

  

	 	16.5	If any Party considers that any Patent is being infringed by a third party, that Party shall notify the other Party and provide it with any evidence of such infringement which is reasonably available. If the
infringement relates to any Agreement Intellectual Property, MERIAL shall have the right, but not the obligation, at its own expense, to attempt to remove such infringement by commercially appropriate steps, including suit which it can settle on
terms it believes commercially reasonable, and all recovery as to which MERIAL may fully retain. If required by MERIAL, SCYNEXIS shall join such suit as a party, at reasonable expense to MERIAL. In any event, SCYNEXIS shall reasonably assist MERIAL
in any such suit, at reasonable expense to MERIAL. 

  

	 	16.6	If any warning letter or other notice of infringement is received by a Party, or action, suit or proceeding is brought against a Party alleging infringement of a Patent of any third party in the manufacture, use
or sale of a Compound or any product developed by MERIAL as a result of this Agreement, MERIAL shall have the right to control responding to such allegation and will reasonably consult with SCYNEXIS. Except as set forth above, each Party shall be
responsible for responding for its own activities and defending its own activities. 

  

	 	16.7	Any information shared among the Parties in connection with any Patent matters shall be fully subject to the confidentiality provisions set forth in Section 15 herein. Furthermore, the Parties agree that any
information shared at any time in any relation to any Inter Partes Patent Proceeding, including without limitation, initiating, defending, or settling any Inter Partes Patent Proceeding, is subject to joint defense or similar agreements, which the
Parties shall memorialize, in good faith. 

  

	 	16.8	MERIAL, shall, through in-house or outside attorneys solely of its choice, prepare, file, prosecute, and maintain, and control the preparation, filing, prosecution and maintenance of, all applications for
registration of generic names for Compounds pursuant to this Agreement. The Parties hereto expressly agree that the in-house and outside attorneys chosen by MERIAL for this purpose are MERIAL’s counsel and waive any and all actual or potential
conflicts of interest with respect thereto. The preparation, filing, prosecution and maintenance of applications for registration of generic names for compounds pursuant to this Agreement, shall be at MERIAL’s cost. 

 

	 	16.9	Except as set out in Section 16.4, SCYNEXIS agrees that the payments described in Exhibit 2 hereinafter are full and complete compensation for all obligations assumed by SCYNEXIS under this Agreement
and in full satisfaction of any and all fees and royalties to which SCYNEXIS may be entitled by law or otherwise, including without limitation, the law of any country in which SCYNEXIS is resident during the Term. 

  

					
	12/19/2011	 	CONFIDENTIAL	  	 Page
 13

 [*] = Certain confidential information contained in this document, marked by brackets, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	16.10	SCYNEXIS represents and warrants that all persons performing Services, be they an employee of SCYNEXIS or a third party engaged by SCYNEXIS, shall be obligated as a matter of law, or shall have entered into
agreements with SCYNEXIS obligating them, to assign to SCYNEXIS all rights they may have in Agreement Intellectual Property (whether patentable or not), and works of original authorship. 

 

	 	16.11	SCYNEXIS agrees to hold all Agreement Intellectual Property confidential in accordance with Section 15 of this Agreement. 

 

	 	16.12	The Parties acknowledge that this Agreement is executory, and that any intellectual property licensed under this Agreement is “licensed intellectual property” for purposes of Section 365(n) of the
US Bankruptcy Code and that each licensee under this Agreement shall have the ability to exercise all rights provided by Section 365(n) with respect to the “licensed intellectual property” in any bankruptcy of a licensor under this
Agreement. 

  

	17.	Insurance. 

  

	 	17.1	SCYNEXIS represents that SCYNEXIS carries and will maintain during the Term of this Agreement: 

  

	 	i)	Workers’ compensation and automobile liability insurance in conformity with the laws of the state(s) in which the work contemplated by this Agreement is to be done; and 

 

	 	ii)	Comprehensive general liability insurance and/or an umbrella liability insurance policy, with combined limits sufficient to cover its potential liabilities under this Agreement. 

 

	 	17.2	SCYNEXIS shall furnish insurance certificates showing SCYNEXIS’s compliance with this Section upon MERIAL’s request. 

 

	 	17.3	Should an employee of SCYNEXIS suffer any kind of injury covered by worker’s compensation laws while performing Services under this Agreement, SCYNEXIS represents and warrants that SCYNEXIS’s
employee’s injuries will be covered under SCYNEXIS’s worker’s compensation insurance policy. 

  

	18.	Assignment and Subcontracting. 

 SCYNEXIS will not assign, delegate, sub-contract,
transfer, charge or otherwise dispose of all or any of its rights and responsibilities under this Agreement without the prior written consent of MERIAL provided that, subject to Section 10.5, SCYNEXIS shall be entitled to assign this Agreement
to any parent, subsidiary, Affiliate, successor of all or substantially all of its [*] assets or business, or related company of SCYNEXIS, [*]. MERIAL reserves the right to assign this Agreement to any parent, subsidiary, Affiliate, successor of all
or substantially all of its assets or business, or related company of MERIAL. This Agreement shall be binding upon and inure to the benefit of the Parties hereto, their Affiliates, and their respective successors and permitted assigns. 

  

					
	12/19/2011	 	CONFIDENTIAL	  	 Page
 14

 [*] = Certain confidential information contained in this document, marked by brackets, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	19.	Representations and Warranties 

  

	 	19.1	Authorization 

 Each Party represents and warrants to the other Party that it has the
legal right and power to enter into this Agreement, to extend the rights and licenses granted to the others in this Agreement, and to fully perform its obligations hereunder, and that the performance of such obligations will not conflict with its
charter documents or any agreements, contracts, or other arrangements to which it is a party. 
  

	 	19.	SCYNEXIS Intellectual Property Rights 

  

	 	i)	SCYNEXIS represents and warrants that it owns or has the right to use pursuant to license, sublicense, agreement or permission all Intellectual Property individually or in the aggregate, that are material to the
operation of its business and are used to render the Services. To the best of its knowledge, SCYNEXIS has not interfered with, infringed or misappropriated any Intellectual Property of third parties. To the best of SCYNEXIS’s knowledge, the
performance of services by SCYNEXIS hereunder, will not interfere with, infringe or misappropriate any Intellectual Property of third parties. SCYNEXIS represents and warrants that it has not received any charge, complaint, claim, demand or notice
alleging any such interference, infringement or misappropriation (including any claim that it must license or refrain from using any Intellectual Property of any third party). To the best knowledge of SCYNEXIS, no third party has interfered with,
infringed upon or misappropriated any Intellectual Property of SCYNEXIS. 

  

	20.	Force Majeure. 

 Either party shall be excused from performing its obligations under this
Agreement if its performance is delayed or prevented by any event beyond such party’s reasonable control, including without limitation, acts of God, fire, explosion, weather, disease, war, insurrection, civil strife, riots, government action,
curtailment of transportation, or power failure, provided that such performance shall be excused only to the extent of and during such disability. Prompt notice of an inability to perform will be provided to the other party. If such force majeure
circumstances occur, the party injured by the other party’s inability to perform may elect to (a) terminate this Agreement immediately if such force majeure event is not cured within [*]; and/or (b) suspend this Agreement for the
duration of the force majeure circumstances, and then resume performance under this Agreement. The party experiencing the force majeure circumstances shall cooperate with and assist the injured party in all reasonable ways to minimize the impact of
such circumstances on the injured party. 
  

	21.	Notices. 

 Any notice or other communication under this Agreement shall be in writing and
shall be effective upon the earlier of (i) actual receipt, (ii) seven (7) days following deposit into the United States mail (certified mail, return receipt requested), (iii) the next business day following deposit with a
nationally recognized overnight courier service, or (iv) the same day following transmission of a legible facsimile copy during regular 

  

					
	12/19/2011	 	CONFIDENTIAL	  	 Page
 15

 [*] = Certain confidential information contained in this document, marked by brackets, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
business hours, in each case with any delivery fees pre-paid and addressed to the party at the address set forth on the first page of this Agreement, Attention General Counsel, or such other
address as that party may notify the other from time to time in accordance with this Section. 
 If to SCYNEXIS, to: 

SCYNEXIS, Inc. 
 P.O. Box 12878
Research Triangle Park, 
 North Carolina 27709, USA 

Attention:    General Counsel 

Facsimile:    +1 919-544-8697 

If to MERIAL, to: 
 Merial Limited

 3239 Satellite Boulevard 

Building 500 
 Duluth, Georgia
30096, USA 
 Attention: General Counsel 

Copy to: Global Head, Intellectual Property 

Facsimile: +1 678-638-3886 
  

	22.	Scope of Agreement. 

 This Agreement shall constitute the entire understanding of the
parties hereto. No modification, amendment or waiver may be accomplished to the terms of this Agreement except in a writing signed by authorized representatives of both parties. 

The waiver by a party of a breach of any provision of this Agreement by the other party (a “Breaching Party”) shall not operate or be
construed as a waiver of any subsequent breach by the Breaching Party. The parties expressly agree that all terms and provisions herein shall be construed and enforced in accordance with the laws of the State of Georgia, without reference to any
rules of conflict of laws. The parties agree that the provisions of this Agreement are severable and separate from one another and if any provision of this Agreement is held to be invalid, illegal, or unenforceable under any present or future law,
such provision shall be modified to the minimum extent necessary to render it enforceable and to preserve to the fullest extent possible its original scope. The parties further agree that if any provision is held to be invalid, illegal, or
unenforceable to such an extent that it cannot be modified and is stricken from the Agreement, the remainder of the Agreement shall be enforceable without regard to the enforceability of any stricken provision. 

 

	23.	Headings. 

 Paragraph headings are for convenience of reference only and shall not be
considered in the interpretation of this Agreement. 
  

	24.	Counterparts 

 This Agreement may be executed in counterparts, each of which shall be
deemed an original, and all of which together shall be deemed to be one and the same instrument. 

  

					
	12/19/2011	 	CONFIDENTIAL	  	 Page
 16

 [*] = Certain confidential information contained in this document, marked by brackets, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their duly
authorized representatives as of the Effective Date. 
  

									
	MERIAL LIMITED	 		 	SCYNEXIS, INC.
					
	By:	 	 /s/ Jose Barella
	 		 	By:	 	 /s/ Yves Ribeill

					
	Name:	 	 Jose Barella
	 		 	Name:	 	 Yves Ribeill

					
	Title:	 	 Senior Vice President, Animal Health
	 		 	Title:	 	 CEO

				
	MERIAL LIMITED	 		 		 	
					
	By:	 	 /s/ Ellen de Brabander
	 		 		 	
					
	Name:	 	 Ellen de Brabander
	 		 		 	
					
	Title:	 	 Head of Global R&D
	 		 		 	

  

					
	12/19/2011	 	CONFIDENTIAL	  	 Page
 17

 [*] = Certain confidential information contained in this document, marked by brackets, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT 1 — SCOPE OF SERVICES 

SCYNEXIS shall perform the following Services: 
 [*] 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT 2 - TERMS 
  

	1.	The total cost for the Services over the Term of the Agreement is $[*]. The cost cannot exceed this amount without MERIAL’s prior written consent. This budget is based on the use of the materials described
in the Scope of Services and any other material, supplies, and services necessary to complete the Services. 

 Payment shall be
made in quarterly installments of $[*]. The quarters will begin on January 1, April 1, July 1 and October 1. The first quarterly installment can be invoiced no sooner than December 1, 2011, after execution of the
Agreement by both parties. The remaining installments will be paid by the later of [*] after MERIAL’s receipt of an invoice from SCYNEXIS or [*] after the start of each quarter and MERIAL’s receipt of an invoice from SCYNEXIS. 

For the avoidance of doubt, MERIAL will be responsible for paying third parties engaged by MERIAL to provide complimentary services as set out
in Section 2.2 above. SCYNEXIS shall be responsible for paying any third parties it engages (with MERIAL’s prior written approval) to provide the Services. SCYNEXIS shall be responsible for paying for its employees’ travel expenses
within the United States of America and to and from Europe. 
  

	2.	Invoices are required for all payments including initial payment and are due [*] days of receipt of invoice. Invoices should be sent to: 

Christian Miculka 

MERIAL LIMITED 
 3239
Satellite Blvd. 
 Duluth, GA 30096-4640 

Payee Name: SCYNEXIS, Inc. 

Payment Method: Wire Transfer 

Complete the following information for wire transfers: 

Bank ABA#: [*] 
 Bank Name: [*]

 Bank Address: [*] 
 Bank
Account Number: [*] 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}]]